Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. by Tang, Kuo-Tung et al.
1Tang K- T, et al. BMJ Open Gastro 2020;7:e000349. doi:10.1136/bmjgast-2019-000349
Antitumour necrosis factor-α agents and 
development of new- onset cirrhosis or 
non- alcoholic fatty liver disease: a 
retrospective cohort
Kuo- Tung Tang  ,1,2,3 Jean- François Dufour,4,5 Po- Hung Chen,6 
Ruben Hernaez,7,8 Susan Hutfless  6
To cite: Tang K- T, Dufour J- F, 
Chen P- H, et al. Antitumour 
necrosis factor-α agents and 
development of new- onset 
cirrhosis or non- alcoholic fatty 
liver disease: a retrospective 
cohort. BMJ Open Gastro 
2020;7:e000349. doi:10.1136/
bmjgast-2019-000349
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjgast- 2019- 000349).
Received 15 October 2019
Revised 23 November 2019
Accepted 6 December 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Susan Hutfless;  
 shutfle1@ jhmi. edu
Epidemiology
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
Objective Elevated tumour necrosis factor (TNF)-α has 
been implicated in the progression of liver fibrosis and 
pathogenesis of non- alcoholic fatty liver disease (NAFLD). 
We aim to investigate the impact of anti- TNF-α agents on 
the development of cirrhosis and NAFLD.
Design This retrospective cohort study used a US claims 
database between 1 January 2010 and 31 December 
2016. We identified adult patients with ankylosing 
spondylitis, inflammatory bowel disease, psoriatic 
arthritis or rheumatoid arthritis. Anti- TNF-α agents of 
interest included adalimumab, certolizumab, etanercept, 
golimumab and infliximab. The primary composite 
outcome was the development of new- onset cirrhosis, 
NAFLD or non- alcoholic steatohepatitis (NASH). The 
secondary outcomes were the development of (1) cirrhosis 
and (2) NAFLD or NASH. Propensity score for anti- TNF-α 
agent use was generated by logistic regression. Cox 
proportional hazard models adjusting for the propensity 
score were used with regard to time- varying anti- TNF-α 
agent exposure.
results This study included 226 555 incident patients 
with immune- related diseases. During the median 1.5 
years follow- up, there was an increased hazard with anti- 
TNF-α agent use in regard to liver outcomes (composite 
outcome HR: 1.47, 95% CI 1.27 to 1.70; cirrhosis HR 
1.47, 95% CI 0.96 to 2.23; NAFLD or NASH HR 1.53, 
95% CI 1.32 to 1.77). The composite outcome hazard 
was increased for each immune- related disease (HR 
1.25–1.90).
Conclusion In the short term, we did not observe a 
beneficial effect of anti- TNF-α agent use for development 
of cirrhosis, NAFLD or NASH in patients with immune- 
related diseases.
IntroductIon
The introduction of antitumour necrosis 
factor (TNF)-α agents in the 20th century 
revolutionised the treatment paradigm for 
patients with immune- related diseases.1 Their 
efficacy in achieving disease remission is well 
established in patients with diseases such as 
axial spondyloarthritis, inflammatory bowel 
disease (IBD), psoriatic arthritis (PsA) and 
rheumatoid arthritis (RA), who fail to respond 
to conventional therapy.2–5 Real- world data 
provide an opportunity to examine various 
effects of this new class of drugs, in addition 
to approved indications.6 For example, some 
observational studies implied additional 
benefits including improved insulin resis-
tance7 and reduction of cardiovascular risk in 
anti- TNF-α agent users.8
Cirrhosis accounts for 1.16 million deaths 
per year worldwide, ranking the 11th most 
common cause of death.9 It originates from 
hepatic insult, resultant inflammation and 
then an untoward propagation of fibrosis. 
Hepatic inflammation is also implicated in the 
development and progression of non- alcoholic 
fatty liver disease (NAFLD),10 11 which is an 
increasingly recognised cause of cirrhosis 
worldwide.12 TNF-α, a crucial proinflamma-
tory cytokine, has been recognised as one of 
the earliest participants in a variety of hepatic 
injuries.13 TNF-α antagonism alleviates hepatic 
summary box
What is already known about this subject:
 ► Animal models and human studies implicate the key 
role of tumour necrosis factor (TNF)-α in the pro-
gression of liver fibrosis and pathogenesis of non- 
alcoholic fatty liver disease.
What are the new findings
 ► This study demonstrates real- world data which 
did not show a beneficial effect regarding anti- 
TNF-α agent use for development of cirrhosis or 
non- alcoholic fatty liver disease in patients with 
immune- related diseases.
How might it impact on clinical practice in the 
foreseeable future
 ► This study provides clues with respect to the po-
tential hepatic effect of anti- TNF-α agent use in 
patients with immune- related diseases.
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Figure 1 The study algorithm for identifying patients with immune- related diseases. *The index date, the date of first 
diagnoses for each immune- related disease. AS, ankylosing spondylitis; IBD, inflammatory bowel disease; NAFLD, non- 
alcoholic fatty liver disease; NASH, non- alcoholic steatohepatitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumour 
necrosis factor.
inflammation and even reverses steatosis in rodent models 
of chronic liver diseases, including NAFLD.14–18 Interven-
tional trials also alluded to the potential of anti- TNF-α agent 
in the suppression of hepatic inflammation/steatosis in 
humans. Pentoxiphylline, which inhibits TNF-α, improved 
histological activity in 55 patients with non- alcoholic steato-
hepatitis (NASH).19 In addition, anti- TNF-α agent use led 
to clinical or histological improvement in hepatic inflam-
mation among patients with alcoholic hepatitis or viral 
hepatitis.20–22 On the contrary, some animal studies implied 
a protective role of TNF-α in the liver23 and its antagonism 
may abolish this effect.24
Patients with immune- related diseases are at risk for liver 
damage, including hepatotoxicity of medications, exacer-
bation of underlying chronic viral hepatitis and concomi-
tant autoimmune liver disease.25 NAFLD is also a common 
finding in these patients, with a prevalence around 20%.26 
Thus, the combination of promoters of liver damage in the 
setting of NAFLD might lead to progression from simple 
steatosis to cirrhosis. We hypothesised that anti- TNF-α 
agent could reduce the risk for development of cirrhosis, 
NAFLD or NASH among patients with immune- related 
diseases. We, therefore, conducted a retrospective cohort 
study based on a claims database in the USA.
Methods
study population
This study analysed data obtained from the MarketScan 
Commercial Claims Database. We first identified adult (≧ 
18) patients with International Classification of Diseases 
(ICD)-9 CM or ICD-10- CM diagnosis codes listed on at 
least two claims on different dates for ankylosing spondy-
litis (AS), IBD (Crohn’s disease and/or ulcerative colitis), 
PsA or RA from 1 January 2010 to 31 December 2016 
(figure 1). Patients with one of these immune- related 
diseases enrolled in the database ≧ 12 months before the 
index date (the date of first diagnosis for the immune- 
related disease) were eligible. Exclusion criteria included 
any claim for systemic lupus erythematosus, systemic scle-
rosis, autoimmune myositis or systemic vasculitis during 
enrolment in the database, to generate a more homoge-
neous study population. We also excluded prevalent cases 
of cirrhosis, NAFLD, NASH or chronic hepatitis B/C on 
or prior to the index date, or anti- TNF-α agent use prior 
to the index date.
Medications of interest
Anti- TNF-α agents included adalimumab, certolizumab, 
etanercept, golimumab and infliximab. The identifi-
cation of anti- TNF-α agent was based on both medica-
tion prescription claims using the National Drug Code 
numbers and administration claims based on Current 
Procedural Terminology codes (online supplementary 
table S1). The beginning of anti- TNF-α agent coverage 
was defined as the date of first anti- TNF-α agent claim. 
The end of anti- TNF-α agent coverage was defined as the 
last date of anti- TNF-α agent use based on prescription 
claims (date of prescription plus supply days) or admin-
istration claims (date of procedure plus a recommended 
dosing interval) (online supplementary table S2). Gaps 
of 84 days or fewer between anti- TNF-α agent use were 
considered continuous use.
Liver outcomes
The primary outcome was the development of a 
composite of cirrhosis (ICD-9- CM code 571.5; ICD-10- CM 
code K74.6x), NAFLD (ICD-9- CM code 571.8; ICD-10- CM 
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codes K76.0) or NASH (no ICD-9- CM code available; 
ICD-10- CM code K75.81, after October 2015) with ≧two 
claims on different days. The two secondary outcomes 
were the development of either cirrhosis or NAFLD/
NASH, for ≧ two claims on different days. The first quali-
fying claim was considered the outcome date.
Potential confounders
Potential confounders included comorbidities and medi-
cations (online supplementary table S1). Diabetes mellitus- 
related claims on or prior to the index date were collected. 
Steatogenic medications (corticosteroids and metho-
trexate) and other hepatotoxic medications (leflunomide, 
azathioprine and sulfasalazine) on or prior to the index 
date were captured. Patients having two prescription claims 
within 84 days since the index date were regarded as medi-
cation users. Use of other biologics, such as anti- interleukin 
(IL)-6 (tocilizumab), anti- IL-12/23 (ustekinumab), anti- 
IL-17 (secukinumab, ixekinumab), abatacept or rituximab 
from the index date through the end of follow- up, was also 
identified based on both prescription and administration 
claims.
Propensity score
In order to control for observed confounders, a propensity 
score for anti- TNF-α agent use was calculated using logistic 
regression to adjust for difference in characteristics between 
anti- TNF-α agent users and non- users among patients with 
each immune- related disease (online supplementary table 
S3). A propensity score was created for each outcome 
because time- to- event analyses were used. Variables that 
are potentially associated with anti- TNF-α agent use or liver 
outcomes (age at index date, sex, diabetes mellitus, corti-
costeroids use, methotrexate use, other hepatotoxic medi-
cations use and other biologics use) were included in the 
propensity score models.
statistics
Cohort characteristics were summarised as medians plus 
range and percentages. Anti- TNF-α agent non- users were 
followed from the index date until the occurrence of the 
outcome, or the end of enrolment in the database, which-
ever came first. Anti- TNF-α agent users were followed from 
the index date until the occurrence of the outcome, or the 
end of anti- TNF-α agent coverage, whichever came first. 
The incidence rate per 10 000 person- years for outcomes 
in anti- TNF-α agent- exposed periods and non- exposed 
periods was calculated. The HRs for outcomes in anti- 
TNF-α agent- exposed periods compared with non- exposed 
periods (treating anti- TNF-α agent exposure as a mono-
tonic time- varying variable) were obtained using the Cox 
proportional hazards model for all patients and patients 
with each immune- related disease and included adjustment 
for propensity score. The proportional hazard assumption 
was checked by including time- by- covariate interactions 
in the model.27 If the proportional hazard assumption 
was violated, a piecewise Cox model was applied.28 In 
the piecewise Cox model, we assumed disparate constant 
proportional hazards before and after a certain timepoint. 
Such a violation occurred for IBD so we took the following 
steps: after examination of the survival curve constructed in 
the method of Simon and Makuch,29 we tested several cut- 
off time points and selected the one with the lowest Akaike 
information criterion. The need for informed consent was 
waived based on the deidentified nature of the claims data-
base. Statistical analyses were conducted using SAS software 
V.9.4 (SAS Institute).
sensitivity analyses
We performed several sensitivity analyses for primary 
composite outcome. First, we examined whether having 
one code only rather than two had a meaningful change 
in the inference. Second, we determined rates of clinical 
encounter, liver function test or liver sonography per year 
for each anti- TNF-α agent use and non- use period (within 
the first 84 days or the whole period) to detect potential 
surveillance bias (online supplementary table S4). We 
found that the difference was most prominent in regard to 
rate of clinical encounter within the whole period. We then 
adjusted for the rate of clinical encounter within the whole 
period as a time- varying covariate based on anti- TNF-α 
agent use and non- use period in the Cox model. Third, 
we examined if restricting patients to those who did not 
use methotrexate or corticosteroids changes the results. 
Finally, patients with other chronic liver diseases which are 
associated with cirrhosis (autoimmune hepatitis, primary 
biliary cirrhosis, primary sclerosing cholangitis, Wilson’s 
disease, hemochromatosis, alpha-1- antitrypsin deficiency 
and alcoholic liver disease) were excluded before analyses. 
We also stratified our analyses by age, sex, methotrexate 
and hepatotoxic medications use.
resuLts
Baseline characteristics of identified patients
RA patients were older, and had the highest propor-
tion of females, diabetes mellitus, hypertension, dyslip-
idaemia and use of corticosteroids among all patients 
with immune- related diseases (table 1). Methotrexate, 
other hepatotoxic medications and other biologics were 
used most often in PsA patients. The median follow- up 
period was around 1.5 years for each immune- related 
disease.
characteristics of anti-tnF-α agent users and non-users
The order of proportion of anti- TNF-α agent use by 
disease was as follows: PsA >AS > RA>IBD. Anti- TNF-α 
agent non- users were older, and had a higher proportion 
of diabetes mellitus, hypertension, dyslipidaemia and a 
lower proportion of use of corticosteroids, methotrexate 
and other hepatotoxic medications, than anti- TNF-α 
agent users among patients with immune- related disease 
(table 2). The median time period of anti- TNF-α agent 
use was around 8 months (0.7 years) for each immune- 
related disease.
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the impact of anti-tnF-α agent use on the development of 
liver outcomes
Overall, anti- TNF-α agent use was associated with an 
increased risk for the composite liver outcome when 
compared with periods of non- use (HR 1.47, 95% CI 1.27 
to 1.70) (table 3). This hazard was similar across diseases 
with the exception of IBD which was further increased 
(HR in the piecewise Cox model greater than 4 years: 
3.41 95% CI 1.67 to 6.96). There was an increased risk for 
cirrhosis (HR 1.47, 95% CI 0.96 to 2.23), and an increased 
risk for NAFLD or NASH (HR 1.53, 95% CI 1.32 to 1.77) 
in patients with immune- mediated diseases.
sensitivity analyses
Sensitivity analyses using one encounter to define liver 
outcomes produced attenuated results compared with 
our case definition requiring two encounters (table 4). 
Adjustment for rates of clinical encounter also attenu-
ated our results. Exclusion of patients with other chronic 
liver diseases did not influence our results. The results 
did not qualitatively change after restricting to patients 
who did not use MTX or corticosteroids. There appeared 
to be a decreasing HR for the composite liver outcome as 
regards to anti- TNF-α agent use with increasing age; in 
males; and in users of hepatotoxic medications.
dIscussIon
Anti- TNF-α agent became an inseparable part of the 
treatment strategy for immune- related diseases in recent 
decades. In view of the potential role of TNF-α in the 
hepatic inflammatory response based on animal studies, 
we anticipated that anti- TNF-α use would lead to a 
decreased risk for cirrhosis, NAFLD or NASH in humans. 
However, we did not replicate these findings in this 
claims- based retrospective cohort study.
Previous human studies indicated a potential benefi-
cial role of anti- TNF-α agent in the treatment of hepatic 
inflammation in alcoholic hepatitis21 22 and chronic hepa-
titis C,20 though limited in clinical efficacy.30 31 Hepatic 
inflammation could both initiate and maintain fibrogen-
esis, culminating in cirrhosis.32 A previous study of 48 
PsA patients receiving anti- TNF-α agent showed that the 
progression of hepatic steatosis was halted 12 months later 
if minimal disease activity was achieved, when compared 
with those who maintained active disease.33 Determi-
nation of liver stiffness in 43 PsA patients found lower 
values in those treated with ant- TNF-α agent, suggesting 
an antifibrotic effect.34 Therefore, anti- TNF-α agent 
use might in turn withhold the progression to cirrhosis 
in chronic liver disease. However, we demonstrated no 
benefit with regard to anti- TNF-σ agent use in the devel-
opment of cirrhosis. The reasons underlying our obser-
vations are uncertain, but several explanations can be 
proposed. Patients treated with anti- TNF-α agent were 
more closely monitored by physicians. This might lead 
to more frequent diagnoses for cirrhosis, although moni-
toring for hepatotoxicity is also recommended in other 
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Table 3 Incidence rates and adjusted HRs for liver outcomes with respect to periods of anti- TNF-α agent use in patients with 
immune- related diseases
Overall AS IBD PsA RA
Incidence rate
(per 10 000 person- years)
Composite outcome of cirrhosis, NAFLD or NASH
  Anti- TNF-α agent use 76.4 92.7 88.7 79.0 65.0
  Anti- TNF-α agent non- 
use
64.7 52.8 67.8 72.7 60.7
Cirrhosis
  Anti- TNF-α agent use 8.7 5.8 15.7 7.8 4.8
  Anti- TNF-α agent non- 
use
9.3 5.3 12.1 7.0 6.6
NAFLD or NASH
  Anti- TNF-α agent use 72.6 86.2 77.2 71.6 68.1
  Anti- TNF-α agent non- 
use
57.4 50.9 57.9 66.5 56.0
Adjusted HR with 
respect to anti- TNF-α 
agent use (95% CI)
  Composite outcome 1.47
(1.27 to 1.70)
1.90
(1.09 to 3.31)
≤4 years:*
1.58
(1.22 to 2.05)
>4 years:*
3.41
(1.67 to 6.96)
1.25
(0.88 to 1.76)
1.30
(1.03 to 1.65)
  Cirrhosis 1.47
(0.96 to 2.23)
1.69
(0.20 to 13.96)
1.99
(1.12 to 3.51)
1.54
(0.51 to 4.61)
1.10
(0.48 to 2.57)
  NAFLD or NASH 1.53
(1.32 to 1.77)
1.81
(1.02 to 3.21)
≤4.5 years:*
1.59
(1.21 to 2.08)
>4.5 years:*
3.90
(1.60 to 9.48)
1.21
(0.84 to 1.74)
1.47
(1.16 to 1.85)
*Results of a piecewise Cox model due to a significant time interaction with anti- TNF-α agent use. After examination of the survival curve 
constructed in Simon and Makuch’s method, several cut- off time points were tested and the one with the lowest Akaike information criterion was 
selected.
AS, ankylosing spondylitis; IBD, inflammatory bowel disease; NAFLD, non- alcoholic fatty liver disease; NASH, non- alcoholic steatohepatitis; PsA, 
psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
hepatotoxic medication users35 and adjustment for clin-
ical encounter rate in the sensitivity analysis did not qual-
itatively change the results. We excluded the possibility 
that the imbalance in methotrexate use was the reason 
for more cirrhosis by performing an analysis restricted to 
patients who did not take methotrexate. It can be argued 
that patients receiving anti- TNF-α agent were sicker and 
might drink more heavily. Finally the drugs themselves 
might be incriminated. Previous reports implied poten-
tial hepatotoxicity of anti- TNF-α agent, including idiosyn-
cratic hepatic injury and autoimmune hepatitis.36
In the rat models, previous experiments implied a pivot 
role of TNF-α in the pathogenesis of NASH.11 Adminis-
tration of infliximab could reverse diet- induced hepatic 
steatosis in rats.17 18 The sonographic stage of NAFLD 
also correlated with serum levels of TNF-α in individuals 
with morbid obesity.10 Pentoxyphylline is therapeutic 
for NASH perhaps through its inhibition of TNF-α.19 
These findings imply the contributing role of TNF-α in 
the generation of hepatic steatosis. In the present study, 
however, we found an increased risk for development of 
NAFLD or NASH in patients with regard to anti- TNF-α 
agent use. Previous observations are conflicting in this 
regard. Likhitsup et al demonstrated a high prevalence 
(54%) of NAFLD in 80 IBD patients under anti- TNF-α 
agent therapy.37 A meta- analysis of five studies in patients 
with IBD found mixed results, in which some studies even 
suggested an increased risk of NAFLD in anti- TNF-α agent 
users.38 Possible explanations for our findings include 
surveillance bias, as elaborated above. We excluded the 
possibility that the imbalance in methotrexate or cortico-
steroids use was the reason for more NAFLD or NASH by 
performing an analysis restricted to patients who did not 
take methotrexate or corticosteroids. There remains the 
possibility that patients requiring anti- TNF-α therapy are 
sicker and therefore less mobile and more prone to gain 
weight and develop NAFLD or NASH. Finally, several 
reports demonstrated that anti- TNF-α agent use are 
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associated with weight gain39–42 and this may be related 
to an increased risk for NAFLD.43 Long- term studies are 
needed to identify these possible mechanisms.
Despite a well- documented pathogenic role, TNF-α is 
also found to plays a protective role in the liver. Animal 
studies have shown the cytoprotective function of TNF-α, 
which is partially mediated by nuclear factor kappa light 
chain enhancer of activated B cells.23 44 A hepatic prolif-
erative response is found in rats after systemic adminis-
tration of TNF-α.45 Antagonism by anti- TNF-α antibody 
suppresses rat liver regeneration after partial hepatec-
tomy46 and aggravates hepatic steatosis in an acute liver 
injury rat model elicited by carbon tetrachloride.24 The 
crucial balance between beneficial and detrimental 
effects of TNF-α in hepatic microenvironment may also 
contribute to our findings.
There are several limitations of our study. Infor-
mation regarding disease activity, overweight/obesity 
and smoking and alcohol status could not be reliably 
obtained in our database.47 The diagnoses of NAFLD, 
NASH or cirrhosis based on claims have inherent impre-
cision and may be underestimated, especially at base-
line.48 Our anti- TNF-α agent non- users received a lower 
proportion of corticosteroids, methotrexate and other 
hepatotoxic medications, which possibly reflected a 
lower disease activity in anti- TNF-α agent non- users. 
This might partly explain our findings in terms of the 
development of cirrhosis, NAFLD or NASH, although 
a previous population- based study did not demonstrate 
an increased risk for cirrhosis in patients with AS, PsA 
and RA when compared with controls without immune- 
related diseases.25 The relatively short period of median 
follow- up (1.5 years) and anti- TNF-α agent use (8 
months) limited interpretation of our findings if there 
is a short- term increase in liver outcomes followed by a 
decrease in liver outcomes. Neither could we distinguish 
dose/duration differences with regard to anti- TNF-α 
agent use. However, we did not find a significant viola-
tion of proportional hazard assumption over time (up 
to around 6 years) in a substantial number of patients 
based on most of our models. For some models (patients 
with IBD) with assumption violations, we did not observe 
a decreased hazard over time in the piecewise analyses. 
To overcome limitations mentioned above, data from 
biological registries are expected to provide more sound 
evidence.6
In conclusion, in contrast to our hypothesis, we did not 
find a decreased hazard for development of cirrhosis, 
NAFLD or NASH with respect to anti- TNF-α agent use in 
patients with immune- related diseases.
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